Trial Search Results
Glaser Obesity Study
This study will determine if the drug metformin, coupled with diet and exercise counseling, will help obese adolescents lose weight.
Stanford is currently not accepting patients for this trial.
Glaser Pediatric Research Network
Collaborator: Elizabeth Glaser Pediatric AIDS Foundation
- Drug: glucophage XR
Phase 2/Phase 3
- Subjects must be between the ages of 13.00 and 17.99 at week 0 (Baseline).
- Subjects must have a BMI ≥ 95th percentile for age and gender using the CDC data (see
Appendix), but must weigh less than 300 pounds (<136 kilograms) when measured during
the initial physical exam at week 0 (Baseline). BMI will be calculated as follows;
weight in kilograms [height in meters]2. This cutoff has been established due to the
weight-bearing limits of the table used in performing the DXA scan. Once enrolled, if
a subject’s weight progresses above 300 pounds, s/he may continue in the study whether
it is possible to perform DXA or not.
- Completion of informed consent/assent process
- Known diabetes as defined by the American Diabetes Association criteria
- Prior drug therapy to treat diabetes or insulin insensitivity, including any form of
insulin or insulin analogs; or any oral antidiabetic medication; acarbose,
acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, metformin,
pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide or troglitazone.
- Prior use of drugs to aid in weight loss, including but not limited to: Benzphetamine
Hcl, Diethylpropion Hcl, Fenfluramine Hcl, Phendimetrazine Tartrate, Phentermine Hcl,
Orlistat, Sibutramine Hcl Monohydrate, Didrex, Tenuate, Pondimin, Bontril-SR,
Adipex-P, Fastin, Ionamin, Phentrol, Xenical, Meridia.
- Subject is currently taking the following medications at the time of the Screening
visit: Cimetidine, amiloride, digoxin, furosemide, morphine, nifedipine, procainamide,
ranitidine, triamterene, trimethoprim, vancomycin and quinidine, as these medications
may increase metformin levels.
- Subjects will be excluded from the study if they have taken prescription-strength
glucocorticoids (by any route) within three months of the screening visit. Topical
glucocorticoids are acceptable if their strength is no greater than the equivalent of
1% hydrocortisone cream.
- History of any syndrome or medical disorder associated with significant obesity,
including but not limited to: Prader Willi Syndrome, Bardet-Biedl Syndrome, Cohen
Syndrome, Cushing syndrome or disease.
- Prior surgical therapy for obesity
- Subject to be excluded if s/he has attended a formal weight loss program within 6
months prior to the Screening visit.
- In the 6 months prior to Screening, subject has consumed alcohol more frequently than
twice per week and/or subject has had more than three alcohol-containing beverages in
a 24 hour period.
- Elevated creatinine (> 1.2 mg/dl)
- Untreated disorders of thyroid function
- Elevated liver enzymes (Alanine Aminotransferase [ALT] or Aspartate Aminotransferase
[AST]) > 80 (approximately 2 times upper limit of normal)
- Mobility impairment that prevents full participation in recommended physical activity
- Other serious medical condition that the Principal Investigator or Lead Site
Investigator determines may put the patient at undue risk if enrolled in the study
- Unable to comply with the protocol in the opinion of the Principal Investigator or the
Lead Site Investigator
- Subjects with child-bearing potential who are unwilling to remain abstinent or use an
effective method of birth control
- Previous pregnancy
Ages Eligible for Study
13 Years - 18 Years
Genders Eligible for Study